TC BioPharm Signs Second Non-Binding Letter of Intent for CAR-T Therapy Acquisition

EDINBURGH, Scotland, May 6, 2024 — TC BioPharm (Holdings) PLC, a clinical-stage biotechnology firm listed on NASDAQ under TCBP, has disclosed the signing of a non-binding letter of intent to acquire a privately-owned biotechnology company specializing in Chimeric Antigen Receptor T-cell (CAR-T) therapies. This acquisition aims to tackle refractory cancers and solid tumors, marking the second such agreement in recent months and underscoring TC BioPharm's aggressive M&A strategy to broaden its therapeutic scope.

CAR T-cell therapy involves modifying a patient's immune cells to enhance their ability to recognize and destroy cancer cells. The acquisition target has pioneered several proprietary techniques to re-engineer CARs, enabling more effective targeting of solid tumors. Pre-clinical proof of concept data has already indicated the therapeutic potential of its lead CAR-T candidate for various solid tumors, including colorectal, pancreatic, mesothelioma, ovarian, and breast cancers. Additionally, the company is advancing a novel allogeneic CAR-T therapy aimed at treating autoimmune diseases.

The completion of this transaction is contingent upon the execution of definitive agreements, the fulfillment of negotiated conditions, securing adequate financing, and obtaining necessary third-party approvals, including governmental consents and clearances. There is no guarantee that the deal will be finalized under the current terms or within the anticipated timeframe.

Bryan Kobel, CEO of TC BioPharm, expressed his enthusiasm about this potential acquisition, highlighting the strong synergies between the two companies. He emphasized that the acquisition would enhance TC BioPharm's existing gamma-delta T-cell platform while expanding their efforts into autoimmune diseases. The fusion of expertise in gamma delta and alpha beta T-cells, along with CAR engineering, is expected to drive significant advancements in their therapeutic offerings, particularly in solid tumor treatments.

Kobel noted that the combined strengths of both companies would provide a robust platform for investors and patients, aiming to develop next-generation cell therapies for multiple indications. He also mentioned that this acquisition could lead to pivotal data points in 2024 and 2025 across various pipeline assets. Despite a challenging capital market environment, TC BioPharm has successfully identified complementary resources that promise to enhance the company's overall value.

TC BioPharm is at the forefront of gamma-delta T cell therapy development. These immune cells, which possess characteristics of both the innate and adaptive immune systems, can naturally distinguish between healthy and diseased tissues. The company is the leader in this space and has pioneered phase II/pivotal clinical studies in oncology. Currently, TC BioPharm is running two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a Phase 2b/3 pivotal trial for OmnImmune®, aimed at treating acute myeloid leukemia using their proprietary allogeneic CryoTC technology to supply frozen products to clinics globally.

In conclusion, this strategic acquisition aligns with TC BioPharm’s mission to expand its therapeutic platform and enhance its capabilities in treating various cancers and autoimmune diseases. The combined expertise and technology are expected to deliver significant advancements in cell therapy, benefiting a wide range of patients and providing a compelling investment opportunity.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!